法国住院患者骨纤维异常增殖症的患病率与相关表现:健康数据库研究
本研究利用法国国家健康保险数据库回顾性识别2012–2024年住院的骨纤维异常增殖症(FD)/McCune-Albright综合征(MAS)患者,其中60%为多骨型FD/MAS。
要点
- 住院患者中60%为多骨型FD/MAS,63%为女性,26%为儿童。
- 每年27%患者使用双膦酸盐,8%使用垂体相关治疗,7.4%补充磷酸盐。
核心结论
- 该全国性研究首次提供法国住院FD/MAS的患病率与发病率估计,但基于住院数据的估计可能低估单骨型FD的真实频率。
研究设计与样本
- 回顾性队列研究,使用法国国家健康保险数据库,纳入2012–2024年住院且主要或伴随诊断为单骨型FD(ICD-10 M85.0)或多骨型FD/MAS(ICD-10 Q78.1)的全部患者,共2249例。
主要发现
- 2012–2024年共2249例患者住院,60%为多骨型FD/MAS,63%为女性,26%为儿童。
- 每年27%患者接受双膦酸盐,7.4%接受磷酸盐补充,3.3%接受芳香化酶抑制剂,8%接受垂体相关治疗,2.2%接受抗甲状腺药物。
关键数值与推荐
- 多骨型FD/MAS采用ICD-10 Q78.1,单骨型FD采用ICD-10 M85.0。
- 相关表现通过住院诊断与门诊药物发放数据评估,以治疗作为替代指标。
临床怎么用
- 内分泌科应关注FD/MAS患者中垂体、甲状腺、磷酸盐代谢及性腺相关表现的筛查与随访。
- 住院编码数据可用于群体层面估计,但需结合门诊编码与临床数据以提高对FD/MAS全谱的识别。
局限性
- 基于住院数据的患病率与发病率估计可能低估单骨型FD的真实频率。
- 相关表现依赖住院诊断与药物发放替代指标,可能遗漏未住院或未用药患者。
- 需改进门诊编码并整合临床数据以更全面反映FD/MAS人群特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fibrous dysplasia (FD)/McCune-Albright syndrome (MAS) is a rare mosaic disorder involving the skeleton and/or extraskeletal manifestations, particularly endocrine features. Population-based estimates of prevalence and incidence are scarce, including in France, and data on associated manifestations mainly derive from specialized centers. This study aimed to estimate the prevalence and incidence of FD/MAS in hospitalized patients in France and to evaluate the frequency of associated manifestations. METHODS: This retrospective cohort study used the French National Health Insurance Database, to identify all patients hospitalized between 2012 and 2024 with a primary or associated diagnosis of monostotic FD (MFD; ICD-10 M85.0) or polyostotic FD/MAS (PFD/MAS; ICD-10 Q78.1). Prevalence and incidence were calculated for 2024. Associated manifestations were assessed using hospitalization diagnoses and outpatient drug dispensing data. RESULTS: Over the 2012-2024 period, 2249 patients were hospitalized in France; 60% had PFD/MAS, 63% were female, and 26% were children. The 2024 prevalence was 5.36 per 1 000 000 inhabitants (95% CI: 4.83-5.94), and the 2024 incidence was 2.58 patients per 1 000 000 inhabitants (95% CI: 2.21-2.99). Regarding associated manifestations, 27% of patients per year received bisphosphonates, 7.4% received phosphate supplements, 3.3% aromatase inhibitors, 8% pituitary treatments, and 2.2% antithyroid agents. CONCLUSION: This nationwide study provides the first estimates of the prevalence and incidence of hospitalized FD/MAS in France, although estimates based on hospitalization data likely underestimate the true frequency of monostotic FD. Treatment-based proxies offer valuable insights into associated manifestations. Improved outpatient coding and integration of clinical data are needed to better capture the full spectrum of FD/MAS at the population level.
引用
- Levaillant L, Coutant R, Rodien P, et al. Fibrous dysplasia in hospitalized patients in France: prevalence and associated manifestations from a health database. J Clin Endocrinol Metab. 2026. PMID: 42161884. doi:10.1210/clinem/dgag209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。